These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2131206)

  • 41. Chronic fatigue: a peculiar evolution of eosinophilia myalgia syndrome following treatment with L-tryptophan in four Italian adolescents.
    Priori R; Conti F; Luan FL; Arpino C; Valesini G
    Eur J Pediatr; 1994 May; 153(5):344-6. PubMed ID: 8033924
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Review of L-tryptophan and eosinophilia-myalgia syndrome.
    Roufs JB
    J Am Diet Assoc; 1992 Jul; 92(7):844-50. PubMed ID: 1624654
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan.
    de Oliveira JS; Auerbach SB; Sullivan KM; Sale GE
    Bone Marrow Transplant; 1993 Feb; 11(2):163-7. PubMed ID: 8435665
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique.
    Shapiro S
    J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Elevated L-kynurenine level and its normalization by prednisolone in a patient with eosinophilia-myalgia syndrome.
    Hisatomi A; Kubota A; Ohashi M; Umeda F; Nawata H; Imamura T; Nagata T
    Fukuoka Igaku Zasshi; 1997 Jan; 88(1):11-7. PubMed ID: 9037890
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Acute pleuropericarditis with eosinophilia after ingestion of tryptophan].
    Dell'Isola B; Rezgui N; Thiollieres JM; Labrousse J; Lissac J; Valcke JC
    Rev Med Interne; 1993 May; 14(5):353-4. PubMed ID: 8235154
    [No Abstract]   [Full Text] [Related]  

  • 47. [A case from practice (233). Eosinophilic myalgia syndrome].
    Hefti U; Steiger U
    Schweiz Rundsch Med Prax; 1991 Dec; 80(50):1421-2. PubMed ID: 1749884
    [No Abstract]   [Full Text] [Related]  

  • 48. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
    Silver RM
    Curr Opin Rheumatol; 1992 Dec; 4(6):851-6. PubMed ID: 1457280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. L-tryptophan syndrome: histologic features of scleroderma-like skin changes.
    Guerin SB; Schmidt JJ; Kulik JE; Golitz LE
    J Cutan Pathol; 1992 Jun; 19(3):207-11. PubMed ID: 1401345
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Animal models of the eosinophilia-myalgia syndrome.
    Clauw DJ
    J Rheumatol Suppl; 1996 Oct; 46():93-7; discussion 92, 97-8. PubMed ID: 8895185
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Topics on eosinophilia-myalgia syndrome].
    Kamatani N
    Nihon Naika Gakkai Zasshi; 1991 Nov; 80(11):1782-7. PubMed ID: 1783846
    [No Abstract]   [Full Text] [Related]  

  • 52. The eosinophilia myalgia syndrome: to be or not to be.
    Espinoza LR
    Semin Arthritis Rheum; 1997 Jun; 26(6):781-4. PubMed ID: 9213375
    [No Abstract]   [Full Text] [Related]  

  • 53. L-tryptophan and the eosinophilia-myalgia syndrome: a clinical and laboratory study.
    McKeon P; Swanwick G; Manley P
    Acta Psychiatr Scand; 1994 Dec; 90(6):451-4. PubMed ID: 7892779
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structural characterization of case-associated contaminants peak C and FF in L-tryptophan implicated in eosinophilia-myalgia syndrome.
    Naylor S; Williamson BL; Johnson KL; Gleich GJ
    Adv Exp Med Biol; 1999; 467():453-60. PubMed ID: 10721088
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk factors for developing eosinophilia myalgia syndrome among L-tryptophan users in New York.
    Back EE; Henning KJ; Kallenbach LR; Brix KA; Gunn RA; Melius JM
    J Rheumatol; 1993 Apr; 20(4):666-72. PubMed ID: 8496862
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Eosinophilia-myalgia syndrome. Clinical aspects and follow-up of 10 patients].
    Mensing H; Schallreuter KU; Senff H; Steinkraus V
    Hautarzt; 1992 Jul; 43(7):436-40. PubMed ID: 1506202
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Eosinophilia myalgia syndrome (EMS) caused by L-tryptophan product and toxic oil syndrome (TOS) caused by denatured rape-seed oil].
    Maitani T; Saitoh H
    Shokuhin Eiseigaku Zasshi; 2009 Dec; 50(6):279-91. PubMed ID: 20065617
    [No Abstract]   [Full Text] [Related]  

  • 58. Intimidation of researchers by special-interest groups.
    Sternberg EM
    N Engl J Med; 1997 Oct; 337(18):1316; author reply 1316-7. PubMed ID: 9380084
    [No Abstract]   [Full Text] [Related]  

  • 59. Safety of 5-hydroxy-L-tryptophan.
    Das YT; Bagchi M; Bagchi D; Preuss HG
    Toxicol Lett; 2004 Apr; 150(1):111-22. PubMed ID: 15068828
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eosinophilic hepatitis: a new feature of the clinical spectrum of the eosinophilia-myalgia syndrome.
    Martinez-Osuna P; Espinoza CG; Cuellar ML; Cabrera GE; Silveira LH; Espinoza LR
    Clin Rheumatol; 1994 Sep; 13(3):528-32. PubMed ID: 7835024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.